Arrowhead Research Corp (NASDAQ:ARWR) Updates On ARC-520 Clinical Data

998

Arrowhead Research Corp (NASDAQ:ARWR) a biopharmaceutical firm advancing targeted RNAi therapeutics, demonstrated results from a Phase 2a clinical trial at The AASLD Liver Meeting 2015®. The report stated that its lead drug ARC-520 against chronic HBV effectively lowered HBV viral antigens resulting from cccDNA.

HBsAg was reduced considerably with a maximum decline of 1.9 logs and a mean maximum decline of 1.5 logs in treatment naïve HBeAg-positive patients. Arrowhead stated that this direct antiviral impact was even recorded 57 days after a single dosage. These results strongly support progress of ARC-520, and company has initiated numerous studies targeted at producing a functional treatment of HBV.

The expert speaks

Christopher Anzalone, Ph.D., the Chief Executive Officer and President of Arrowhead Research Corp (NASDAQ:ARWR), said that at AASLD they presented findings from company’s clinical plan and from a nonclinical trial in chimpanzees. Both of these trials demonstrated that ARC-520 can result in durable and deep reduction of HBV viral antigens.

This report provides the team additional confidence in the clinical program as they move forward with combination and multiple-dose trials of ARC-520 that the company expect will direct to host immune reconstitution, and functional cure.

The presentation

Man-Fung Yuen, M.D., Ph.D., a principal investigator of Phase IIa clinical trial, presented a late-breaking poster demonstration. It stated that ARC-520 produces durable and deep reduction of DNA and viral antigens in a phase 2 trial in patients suffering with chronic hepatitis B. Dr. Yuen showed that in the Heparc-2001 clinical trial, ARC-520 with entecavirrecorded maximum knockdown of HBeAg, HBsAg, HBV DNA, and HBcrAg of 1.7 logs, 1.9 logs, 4.3 logs, and 1.2 logs, respectively.

ARC-520 had a direct antiviral impact after a single dosing that was even noticed after 57 days. Consistent with results from Arrowhead’s chimpanzee trial, also showed at AASLD, disparities in viral antigen reduction implied that patients’ previously cured experimental drug probably had lower levels of cccDNA resulting mRNA transcripts.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.